Active, not recruitingNCT04783428
Tumor-induced Osteomalacia Disease Monitoring Program
Studying Oncogenic osteomalacia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Medical DirectorUltragenyx Pharmaceutical Inc
- Intervention
- No intervention(other)
- Enrollment
- 23 target
- Eligibility
- All sexes
- Timeline
- 2022 – 2032
Study locations (6)
- Yale University, New Haven, Connecticut, United States
- Indiana University, Bloomington, Indiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- University of Virginia, Charlottesville, Virginia, United States
- IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas, Buenos Aires, Argentina
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04783428 on ClinicalTrials.govOther trials for Oncogenic osteomalacia
Additional recruiting or active studies for the same condition.